LingMou Medical Secures Tens of Millions in Pre-A Funding to Accelerate the Era of Full-Scenario Endoscopy

From Domestic Substitution to Domestic Leadership: The Highly Concentrated Landscape of Flexible Endoscopes Is Being Reshaped.

VCBeat has learned at the earliest opportunity that a provider of department-level solutions for flexible endoscopyHangzhou Lingmou Medical Technology Co., Ltd. (hereinafter referred to as “Lingmou Medical”)Announced the completion of a Pre-A financing round amounting to tens of millions of RMB. This round was led byHaibang FenghuaLead investor,LEAP CAPITALServing as the exclusive long-term financial advisor. The proceeds from this financing round will be used to advance the commercialization of the company’s approved products, further strengthen and supplement its endoscopy product portfolio, and enhance its comprehensive competitive advantage.

Cancer looms over humanity like the Sword of Damocles, with digestive system cancers accounting for a particularly significant proportion. According to data from CA: A Cancer Journal for Clinicians and Hongta Securities, digestive system cancers constitute approximately 30% of newly diagnosed cancer cases in China, and this proportion is on the rise. Despite the continuous emergence of various innovative technologies, digestive endoscopy remains regarded as the “gold standard” and an indispensable component of current clinical practice.

China’s demand for digestive system cancer screening remains unmet, while the technological gap between domestically produced and imported endoscopic equipment is narrowing. National policies encourage public medical institutions to procure domestically manufactured devices. Driven by the dual forces of “overall market expansion” and “import substitution,” the potential of the flexible endoscope market is poised to be fully unleashed.

In recent years, domestic medical device companies have made continuous efforts, successively launching Chinese-made flexible endoscopes that have gained recognition from experts and patients, thereby gradually capturing a certain market share. However, the long-term reliance of some domestic flexible endoscopes on upstream supply chains for core components has limited further enhancement of product competitiveness. The complexity of production technologies and processes has affected product consistency and yield rates, making the path to import substitution still arduous and lengthy. Therefore, possessing profound foundational technological accumulation and innovation capabilities is key to accelerating the penetration of Chinese-made flexible endoscopes into core markets.

Since its inception, LYNMOU has simultaneously established its R&D center in Shenzhen and its manufacturing base in Hangzhou. The company is committed to becoming a provider of department-level solutions for flexible endoscopy, leveraging technological innovation and a diversified product portfolio to assist physicians, benefit patients, and empower the industry.

Leveraging robust R&D capabilities and extensive manufacturing experience, LYNMOU has rapidly secured product approvals. Its self-developed and self-manufactured VC-1600 series full-HD electronic endoscopy systems, along with electronic upper and lower gastrointestinal endoscopes, were officially approved in April this year. Pioneering the “Full-Scenario Imaging” concept, the system features four special light imaging modes—HLI, SVI, TCI, and DHI—to comprehensively meet imaging needs across various clinical scenarios, providing a professional, end-to-end imaging solution for the screening, diagnosis, and treatment of early-stage gastrointestinal cancers.

LYNMOU Full-Scenario Electronic Endoscopy System VC-1600 Series

Full-Scenario Imaging

Leveraging its differentiated advantages in all-scenario imaging electronic endoscopy systems, LYNMOU will deliver more efficient, user-friendly, and precise diagnostic and therapeutic tools to clinical practice. With the introduction of multiple national policies supporting the development of primary healthcare resources, continuous regulatory approvals of its products, and strong capital support, LYNMOU, guided by the concept of precision diagnosis and treatment, will continue to launch department-level solutions for flexible endoscopy, further enhancing surgical efficiency and safety.

Meanwhile, LYNMOU is also targeting overseas markets by leveraging domestic and international expert resources and academic exchanges to build an ecosystem network and expand its global presence. The company continues to strengthen its global layout, bringing next-generation endoscopes made with Chinese innovation gradually onto the international stage.

Regarding the securing of this round of financing,LYNMOU Management TeamStatement: LYNMOU has been consistently committed to advancing the development and penetration of flexible endoscopes in China. Since its inception, we have established a research and development system grounded in the fundamental logic of product technology, continuously refining product details to provide higher-quality endoscopic solutions for clinical practice and patients, thereby enabling more at-risk populations to benefit from endoscopic diagnosis and treatment. Building on this foundation, LYNMOU will continue to drive the iteration of new technologies and products to meet the diverse and innovative clinical needs of a broad range of endoscopists. Meanwhile, during this critical period following product certification, we will further strengthen our marketing team’s capabilities, focusing on rapid and efficient commercialization and promotion to achieve breakthrough success in the Chinese endoscopy market.

Haibang FenghuaIt is indicated that reusable digestive endoscopes represent a high-growth sector with substantial market potential within the medical device industry. Procurement data reveals that imported products still dominate hospital purchases, indicating significant room for further substitution with domestically produced alternatives. We have observed that LYNMOU boasts an experienced team, strong R&D capabilities and execution power, as well as a diversified strategy for endoscope portfolio development. Therefore, we are optimistic about and look forward to LYNMOU joining forces with other domestic enterprises to enhance the penetration rate of screening, diagnosis, and treatment for gastrointestinal diseases in China, thereby creating clinical value. In the future, LYNMOU will further expand into overseas markets, showcasing the capabilities of intelligent manufacturing in China to the world.

LEAP CAPITALStatement: Driven by the urgent demand for early diagnosis and screening, and strongly supported by policies promoting the substitution of imported products with domestically produced ones, China’s flexible endoscopy market is witnessing significant growth potential. LYNMOU, grounded in independent R&D, has achieved a balance among product maneuverability, image performance, and reliability through its profound understanding and research of optical imaging, image processing technologies, precision mechanics, and endoscope manufacturing processes. The company has built an endoscopy solution platform covering all clinical scenarios and is committed to establishing a global business layout. LEAP CAPITAL firmly favors LYNMOU’s clinical-oriented technological innovation capabilities and extensive commercialization experience. It will continue to support the company, expecting LYNMOU to become a leading force in China’s domestic flexible endoscopy sector.

Haibang Fenghua was founded by Zhejiang Haibang Investment, a renowned equity investment institution in Zhejiang Province, together with its entire investment management team. The company primarily focuses on early- to mid-stage equity investments in the fields of life and health, the digital economy, and new materials. Adhering to the investment philosophy of “Technology + Talent,” we firmly believe that technology changes the world and are committed to supporting entrepreneurs with great ideals and an entrepreneurial spirit.

LEAP CAPITAL, established in 2019, is committed to becoming the most trusted value-added technology investment bank for entrepreneurs. It provides private placement financial advisory, strategic consulting, and innovation incubation services to companies from the angel stage through Pre-IPO rounds, helping them rapidly establish a leading capital advantage in their respective sectors. Upholding the philosophy of DVA (Deep-Value-Add), LEAP CAPITAL continuously delivers comprehensive empowerment to corporate development from strategic, capital, and resource perspectives. Over the past five years, leveraging its outstanding multidisciplinary team, extensive industry experience, and top-tier operational capabilities, LEAP CAPITAL has successfully risen to become one of China’s leading technology investment banks. To date, it has assisted over 120 companies in completing more than 200 private financing transactions, with a cumulative transaction volume exceeding RMB 40 billion.

References:

1. “Emerging as a New Force: Domestic Endoscopes Usher in the Era of All-Scenario Imaging,” CBL Medical Devices

2. “The ‘Eye’ of Technology Shines in Chongqing—LYNMOU Makes Its Debut at the 17th National Academic Symposium on Early Gastrointestinal Cancer,” LYNMOU

3. “Ling” Mirror Assists Medicine, “Mou” Sees Brilliance—LYNMOU Invites You to CMEF 2024, LYNMOU